Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.
礼来买下Morphic Holding Inc的股票，每股价格为57美元，总额约为32亿美元。
Lead asset MORF-057 is a small-molecule inhibitor that is currently in Phase 2b trial for ulcerative colitis, with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn's disease.
领先资产MORF-057是一种小分子抑制剂，目前正在进行溃疡性结肠炎的20亿期临床试验，预计于2025年上半年揭晓结果。它最近启动了一项克罗恩病的2期研究。
Also Read: Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst.
也阅读：艾默生研究的抗淀粉样抗体疗法广泛适用的标签反映了监管机构对抗淀粉样蛋白的信恳智能的信心：分析师。
Goldman Sachs writes that α4β7 is a clinically validated target in inflammatory bowel disease (IBD), as it notes Takeda Pharmaceutical Company Ltd's (NYSE:TAK) Entyvio generated $5.3 billion sales fiscal year 2023 in UC and Crohn's disease.
高盛表示，α4β7在炎症性肠病(IBD)中是一种临床上验证的靶点，因为它指出武田制药有限公司（纽交所:TAK）的安泰唑在2023财年中在UC和克罗恩病中产生了53亿的销售额。
The analyst notes the proposed deal has strategic merit and would present a potentially helpful step toward strengthening the company's pipeline portfolio in Immunology.
分析师指出，建议的交易具有战略优势，并将是加强公司免疫学管线组合的潜在有益步骤。
Although investors are primarily focused on the obesity franchise's performance and outlook, deals like these are crucial for strengthening the company's diverse therapeutic areas, such as Immunology.
尽管投资者主要关注肥胖治疗应用的表现和前景，但此类交易对于加强公司多样化治疗领域（如免疫学）至关重要。
Despite receiving less attention from investors, Immunology remains an important development area for the company.
尽管受到投资者关注较少，但免疫学仍是公司的一个重要发展领域。
Last year, Eli Lilly acquired DICE Therapeutics, a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop oral therapeutic candidates for immunology indications for $48 per share.
去年，艾默生以48美元的价格收购了DICE Therapeutics，该生物制药公司利用其专有的DELSCAPE技术平台开发口服治疗候选药物，用于免疫学适应症。
Goldman Sachs reiterates the Neutral rating with a price target of $793.
高盛重申中立评级，价格目标为793美元。
Price Action: LLY shares are up 0.72% at $924.64 at last check Tuesday.
股价表现：截至本周二最后一次检查，LLY股价上涨0.72％，为924.64美元。
- Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows.
- 研究表明，艾默生的蒙贾罗在减肥效果方面超越了诺和诺德的奥泽匹克。